Bullish indicating open at $55-$60, IPO prices at $37
Celsius Holdings (NASDAQ:CELH) Inc. stock reached a 52-week high of $53.04, marking a significant milestone for the company. According to InvestingPro data, the company maintains a "GREAT" overall financial health score, with particularly strong momentum and cash flow metrics. This achievement comes as the stock has delivered impressive returns, including a remarkable 123.65% gain over the past six months and a 90.28% increase year-to-date. The rise in stock price aligns with the company’s ongoing growth and expansion efforts in the health and wellness sector, supported by a strong gross profit margin of 50.43% and analysts’ expectations of continued sales growth. The 52-week high underscores the positive momentum Celsius Holdings has maintained, positioning it well in a competitive market. For deeper insights into CELH’s valuation and growth prospects, including 17 additional ProTips and comprehensive analysis, check out the full research report on InvestingPro.
In other recent news, Celsius Holdings reported impressive financial results for the second quarter of 2025, significantly surpassing analyst expectations. The company announced earnings per share of $0.47, nearly double the anticipated $0.24, and revenue of $739.3 million, well above the projected $654.3 million. Following these strong results, several firms have adjusted their outlook on Celsius. TD Cowen raised its price target for the company to $60 from $55, maintaining a Buy rating, citing the successful revival of its core product line’s marketing positioning. UBS also increased its price target to $64 from $57, highlighting the company’s top-line growth and improved margins. Similarly, Jefferies raised its target to $64 from $54, noting the positive impact of the Alani Nu brand’s momentum on Celsius’s sales. These developments reflect a positive sentiment among analysts regarding Celsius’s recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.